FDA 483 - Wuxi Biologics Co Ltd - April 02, 2021
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
WuXi Biologics Co. Ltd. in Mashan, Wuxi, Jiangsu, China, a drug substance and drug product manufacturer, was cited with six observations during an FDA inspection. The observations highlight significant deficiencies in computer system controls, quality unit oversight of documents, inadequate preventative maintenance schedules, and insufficient raw material specifications. Additionally, the firm failed to consistently initiate effectiveness checks for CAPAs and thoroughly investigate product complaints and discrepancies.
ID · c4173103-8401-4432-96e8-f35b570c5cc6